Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology pushbiopharmadive·3 hours agoBIIB-0.62%AZN-1.13%
Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanksbenzinga_article·6 hours agoALNY-28.31%AZN-1.13%
Astrazeneca Plc (NYSE:AZN) Receives Average Recommendation of "Moderate Buy" from BrokeragesMarket Beat·1 day ago, 01:44 AMAZN-1.13%AZN
AstraZeneca declares BRL 0.87 per unit distribution for BRA1ZNBDR 003, payable Sept. 14PUBT·2 days ago, 01:06 PMAZN-1.13%
Evelyn Partners Investment Management Europe Ltd Acquires Shares of 21,991 Astrazeneca Plc $AZNMarket Beat·2 days ago, 05:41 AMAZN-1.13%
AstraZeneca reports Phase III results for Ultomiris and Sone-VeWorldPharmaceuticals·2 days ago, 04:12 AMAZN-1.13%AZN
AstraZeneca's China Revenue Shrinks in First Half Due to Sluggish Flagship Product GrowthYicai·2 days ago, 01:12 AMAZN-1.13%AZN
Goldman Sachs Reaffirms Their Buy Rating on AstraZeneca (AZN)Tip Ranks·2 days ago, 12:35 AMAZN-1.13%AZN
Keymed’s CLDN18.2 Drug CMG901 Delivers Phase III Survival Gain in Gastric CancerTip Ranks·2 days ago, 11:07 PM021620.00%AZN-1.13%
Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquiredrttnews·2 days ago, 10:34 PMFBRX+0.59%TVGNW-7.37%
Pipeline Speed Bump Doesn't Shake AstraZeneca's $80 Billion Revenue Ambitionbenzinga_article·Jul 27 at 07:50 AMAZN-1.13%
